Investigation of the role of the p38 MAPK α and δ isoforms in nonresponse to tumour necrosis factor blockade in the synovium of rheumatoid arthritis patients

被引：0
|
作者：
LR Coulthard
LD Church
RJ Mathews
S Churchman
L Dickie
M Buch
R Reece
A English
AW Morgan
S Gay
P Emery
MF McDermott
机构：
[1] St James's University Hospital,Leeds Institute of Molecular Medicine
[2] University Hospital,Department of Rheumatology
来源：
Arthritis Research & Therapy | / 9卷
关键词：
Rheumatoid Arthritis; Infliximab; Rheumatoid Arthritis Patient; Rheumatoid Arthritis Synovium; ACR20 Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis
    Barrera, P
    Oyen, WJG
    Boerman, OC
    van Riel, PLCM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) : 825 - 828
  • [22] Activation of inflammation, coagulation and fibrinolysis in patients with rheumatoid arthritis: Inhibition by tumour necrosis factor alpha blockade
    Ingegnoli, F.
    Fantini, F.
    Favalli, E.
    Galbiati, V.
    Soldi, A.
    Griffini, S.
    Bonanni, E.
    Cugno, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A30 - A30
  • [23] Blockade of tumour necrosis factor a significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis
    Yazdani-Biuki, B
    Stadlmaier, E
    Mulabecirovic, A
    Brezinschek, R
    Tilz, G
    Demel, U
    Mueller, T
    Brickmann, K
    Graninger, WB
    Brezinschek, HP
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1224 - 1226
  • [24] Effects of tumour necrosis factor alpha blockade on lipid profile in active rheumatoid arthritis
    Del Porto, F.
    Lagana, B.
    Nofroni, I.
    Tinti, F.
    Mitterhofer, A. P.
    D'Amelio, R.
    RHEUMATOLOGY, 2007, 46 (10) : 1626 - 1627
  • [25] Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
    AI Catrina
    S Ernestam
    E af Klint
    L Klareskog
    AK Ulfgren
    Arthritis Res Ther, 6
  • [26] The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis
    Schett, G.
    Zwerina, J.
    Firestein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 909 - 916
  • [27] The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
    Wijbrandts, C. A.
    Dijkgraaf, M. G. W.
    Kraan, M. C.
    Vinkenoog, M.
    Smeets, T. J.
    Dinant, H.
    Vos, K.
    Lems, W. F.
    Wolbink, G. J.
    Sijpkens, D.
    Dijkmans, B. A. C.
    Tak, P. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (08) : 1139 - 1144
  • [28] Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
    Catrina, AI
    Ernestam, S
    Klint, EA
    Klareskog, L
    Ulfgren, AK
    ARTHRITIS RESEARCH & THERAPY, 2004, 6 (Suppl 1) : S9 - S9
  • [29] Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis
    Moreland, LW
    PHARMACOECONOMICS, 2004, 22 (02) : 39 - 53
  • [30] Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis
    Roberts, L
    McColl, GJ
    INTERNAL MEDICINE JOURNAL, 2004, 34 (12) : 687 - 693
12345